Fig 1: (a) Random forests identifying key genes for disease. (b) Kaplan–Meier curves showed overall survival difference between high and low MLH1 expression groups in the TCGA-LIHC cohort (p = 0.037). (c, d) Real time-PCR and Western blot revealed that the expression of MLH1 was notably increased in HCC cell lines. (e, f) Immunohistochemical staining of MLH1 in tumor tissues and normal tissues of HCC patients in the HPA database (100 ×). (g) Expression pattern of MLH1 in the tumor microenvironment by single cell analysis. HCC, hepatocellular carcinoma; HPA, Human Protein Atlas.*p < 0.05, ** p < 0.01.
Fig 2: (a, b) The knockdown levels of MLH1 in Hep 3B cell line were detected by qPCR and western blot. β-actin was used as internal parameter. (c) Cell proliferation capacity was determined by CCK-8 analysis after knockdown of MLH1 in Hep 3B cells. (d) Effect of inhibition of MLH1 expression on colony formation of Hep 3B cells. (e) Effect of inhibition of MLH1 gene expression on apoptosis of Hep 3B cells (f) Wound healing assays revealed that knockdown MLH1 notably inhibited migration ability of Hep 3B cells (100 ×). (g) Transwell assays revealed that knockdown MLH1 notably inhibited migration and invasion of Hep 3B cells (100 ×). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Supplier Page from Abcam for Recombinant Human MLH1 protein (GST tag N-Terminus)